$ZYME's ZW191 ... the most promising anti-FRα ADC to date. Given the previous results of ZW33 and ZW49, that wasn't necessarily to be exp...

AACR 2026 现场信号· @ · X·2026-04-22 06:44· 2026-04-22评分60

正文 · 原文

$ZYME's ZW191 ... the most promising anti-FRα ADC to date. Given the previous results of ZW33 and ZW49, that wasn't necessarily to be expected.

#AACR26 Presentation →

https://t.co/IvPsnbSCkD

热度 15 · 13 赞 · 1 回复 · 1 转发

会议摘要

CT306NCT06555744按代号 ZW191 对上

Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results

Patricia LoRusso, David Sommerhalder, Kosei Hasegawa, Kenichi Harano, David S. Tan, Noboru Yamamoto, David M. O’Malley, Kathleen N. Moore, Sarah E. Church, Lin Lu, Sabeen Mekan, Pranshul Chauha, Jung-Yun Lee

读摘要原文 →

来源：AACR 2026 现场信号 · x.com